Around 80–85% of stroke cases5 in Australia are acute ischaemic stroke, for which intravenous thrombolysis (IVT) with tissue plasminogen activator (alteplase) is the current standard treatment for eligible patients and significantly improves the overall likelihood of a good stroke outcome, compared with usual care.6 This evidence concerns the gene PLAT and Stroke.